Trade Harpoon Therapeutics, Inc. - HARP CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.0640 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026207% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003985% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Harpoon Therapeutics Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 9.948 |
| Open* | 9.798 |
| 1-Year Change* | 1301.72% |
| Day's Range* | 8.788 - 9.918 |
| 52 wk Range | 3.11-33.55 |
| Average Volume (10 days) | 181.91K |
| Average Volume (3 months) | 3.13M |
| Market Cap | 219.95M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 16.93M |
| Revenue | 37.34M |
| EPS | -8.71 |
| Dividend (Yield %) | N/A |
| Beta | 2.26 |
| Next Earnings Date | Mar 25, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 8, 2023 | 8.8980 | -1.1000 | -11.00% | 9.9980 | 9.9980 | 8.7880 |
| Dec 7, 2023 | 9.9480 | -0.0500 | -0.50% | 9.9980 | 10.4480 | 9.7980 |
| Dec 6, 2023 | 9.9280 | -0.6700 | -6.32% | 10.5980 | 11.3980 | 9.4980 |
| Dec 5, 2023 | 10.5080 | 0.5100 | 5.10% | 9.9980 | 10.8080 | 9.6880 |
| Dec 4, 2023 | 10.2380 | -0.3400 | -3.21% | 10.5780 | 11.3280 | 10.1280 |
| Dec 1, 2023 | 10.9880 | 0.8200 | 8.06% | 10.1680 | 11.1180 | 10.0980 |
| Nov 30, 2023 | 10.5980 | 0.1000 | 0.95% | 10.4980 | 11.1980 | 10.0980 |
| Nov 29, 2023 | 10.3080 | 0.1100 | 1.08% | 10.1980 | 10.3880 | 9.5880 |
| Nov 28, 2023 | 10.4580 | 1.0000 | 10.57% | 9.4580 | 10.5480 | 9.4580 |
| Nov 27, 2023 | 9.6480 | -2.1000 | -17.88% | 11.7480 | 11.9980 | 8.6480 |
| Nov 24, 2023 | 11.6780 | -0.5200 | -4.26% | 12.1980 | 12.6080 | 11.6780 |
| Nov 22, 2023 | 12.8380 | -0.1600 | -1.23% | 12.9980 | 14.9780 | 11.4080 |
| Nov 21, 2023 | 12.9380 | 0.6400 | 5.20% | 12.2980 | 13.5180 | 12.0280 |
| Nov 20, 2023 | 12.8080 | 1.4000 | 12.27% | 11.4080 | 13.6880 | 11.4080 |
| Nov 17, 2023 | 11.4080 | 1.8500 | 19.36% | 9.5580 | 11.4480 | 9.4480 |
| Nov 16, 2023 | 9.4180 | 0.9100 | 10.70% | 8.5080 | 9.4980 | 8.4080 |
| Nov 15, 2023 | 8.6780 | 0.2800 | 3.33% | 8.3980 | 9.2380 | 8.2880 |
| Nov 14, 2023 | 8.6480 | 0.8500 | 10.90% | 7.7980 | 8.7680 | 7.5480 |
| Nov 13, 2023 | 7.3080 | 0.8800 | 13.69% | 6.4280 | 7.5680 | 5.9980 |
| Nov 10, 2023 | 6.3280 | 0.0600 | 0.96% | 6.2680 | 6.7280 | 5.9880 |
Harpoon Therapeutics, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, March 25, 2024 | ||
| Time (UTC) 10:59 | Country US
| Event Q4 2023 Harpoon Therapeutics Inc Earnings Release Q4 2023 Harpoon Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 31.915 | 23.654 | 17.444 | 5.777 | 4.75 |
| Revenue | 31.915 | 23.654 | 17.444 | 5.777 | 4.75 |
| Total Operating Expense | 100.24 | 140.405 | 68.775 | 63.983 | 32.474 |
| Selling/General/Admin. Expenses, Total | 18.847 | 18.327 | 16.21 | 22.391 | 6.106 |
| Research & Development | 81.393 | 72.124 | 52.565 | 41.592 | 26.368 |
| Operating Income | -68.325 | -116.751 | -51.331 | -58.206 | -27.724 |
| Interest Income (Expense), Net Non-Operating | 0.776 | 0.24 | 1.449 | 2.676 | 0.395 |
| Other, Net | -0.182 | -0.21 | -0.026 | -0.042 | -0.037 |
| Net Income Before Taxes | -67.731 | -116.721 | -49.908 | -55.572 | -27.366 |
| Net Income After Taxes | -67.731 | -116.721 | -49.908 | -55.572 | -27.366 |
| Net Income Before Extra. Items | -67.731 | -116.721 | -49.908 | -55.572 | -27.366 |
| Net Income | -67.731 | -116.721 | -49.908 | -55.572 | -27.366 |
| Income Available to Common Excl. Extra. Items | -67.731 | -116.721 | -49.908 | -55.572 | -27.366 |
| Income Available to Common Incl. Extra. Items | -67.731 | -116.721 | -49.908 | -55.572 | -27.366 |
| Diluted Net Income | -67.731 | -116.721 | -49.908 | -55.572 | -27.366 |
| Diluted Weighted Average Shares | 3.31674 | 3.22744 | 2.50349 | 2.17465 | 2.3909 |
| Diluted EPS Excluding Extraordinary Items | -20.4209 | -36.1652 | -19.9353 | -25.5545 | -11.4459 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Diluted Normalized EPS | -20.4209 | -20.6873 | -19.9353 | -25.5545 | -11.4459 |
| Total Extraordinary Items | 0 | 0 | |||
| Unusual Expense (Income) | 0 | 49.954 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 20.221 | 8.583 | 4.089 | 13.617 | 8.303 |
| Revenue | 20.221 | 8.583 | 4.089 | 13.617 | 8.303 |
| Total Operating Expense | 15.999 | 19.348 | 22.801 | 25.506 | 25.714 |
| Selling/General/Admin. Expenses, Total | 3.803 | 4.185 | 3.854 | 4.529 | 5.063 |
| Research & Development | 12.196 | 15.163 | 18.947 | 20.977 | 20.651 |
| Unusual Expense (Income) | 0 | 0 | 0 | ||
| Operating Income | 4.222 | -10.765 | -18.712 | -11.889 | -17.411 |
| Interest Income (Expense), Net Non-Operating | -0.945 | 0.287 | 0.343 | 0.289 | 0.104 |
| Other, Net | -2.217 | -0.86 | -0.05 | -0.04 | -0.044 |
| Net Income Before Taxes | 1.06 | -11.338 | -18.419 | -11.64 | -17.351 |
| Net Income After Taxes | 1.06 | -11.338 | -18.419 | -11.64 | -17.351 |
| Net Income Before Extra. Items | 1.06 | -11.338 | -18.419 | -11.64 | -17.351 |
| Net Income | 1.06 | -11.338 | -18.419 | -11.64 | -17.351 |
| Income Available to Common Excl. Extra. Items | 1.061 | -11.338 | -18.419 | -11.64 | -17.351 |
| Income Available to Common Incl. Extra. Items | 1.061 | -11.338 | -18.419 | -11.64 | -17.351 |
| Diluted Net Income | 1.061 | -11.338 | -18.419 | -11.64 | -17.351 |
| Diluted Weighted Average Shares | 3.7973 | 3.69682 | 3.3689 | 3.30621 | 3.30369 |
| Diluted EPS Excluding Extraordinary Items | 0.27941 | -3.06696 | -5.46736 | -3.52064 | -5.25201 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | 0.27941 | -3.06696 | -5.46736 | -3.52064 | -5.25201 |
| Total Adjustments to Net Income | 0.001 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 54.727 | 137.695 | 129.754 | 150.617 | 90.223 |
| Cash and Short Term Investments | 53.112 | 135.098 | 126.03 | 148.073 | 89.493 |
| Cash & Equivalents | 51.614 | 44.687 | 21.17 | 88.736 | 89.493 |
| Total Receivables, Net | |||||
| Prepaid Expenses | 1.615 | 2.597 | 3.724 | 2.544 | 0.73 |
| Total Assets | 73.729 | 155.452 | 171.592 | 176.604 | 102.58 |
| Property/Plant/Equipment, Total - Net | 18.091 | 15.375 | 16.771 | 18.398 | 8.782 |
| Property/Plant/Equipment, Total - Gross | 26.634 | 21.561 | 20.767 | 20.312 | 4.012 |
| Accumulated Depreciation, Total | -8.543 | -6.186 | -3.996 | -1.914 | -1.014 |
| Other Long Term Assets, Total | 0.911 | 0.86 | 1.121 | 0.533 | 3.575 |
| Total Current Liabilities | 52.433 | 59.139 | 47.918 | 22.513 | 11.948 |
| Accounts Payable | 4.712 | 2.666 | 1.572 | 2.594 | 4.357 |
| Accrued Expenses | 16.784 | 19.011 | 15.047 | 8.712 | 3.341 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 30.937 | 37.462 | 31.299 | 11.207 | 4.25 |
| Total Liabilities | 68.33 | 97.382 | 117.753 | 82.384 | 26.482 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 15.897 | 38.243 | 69.835 | 59.871 | 14.534 |
| Total Equity | 5.399 | 58.07 | 53.839 | 94.22 | 76.098 |
| Redeemable Preferred Stock | 0 | ||||
| Common Stock | 0.004 | 0.004 | 0.003 | 0.003 | 0.001 |
| Additional Paid-In Capital | 357.921 | 342.905 | 221.904 | 212.339 | 9.111 |
| Retained Earnings (Accumulated Deficit) | -352.523 | -284.792 | -168.071 | -118.163 | -62.591 |
| Other Equity, Total | -0.003 | -0.047 | 0.003 | 0.041 | 0 |
| Total Liabilities & Shareholders’ Equity | 73.729 | 155.452 | 171.592 | 176.604 | 102.58 |
| Total Common Shares Outstanding | 3.57867 | 3.27658 | 2.55532 | 2.49048 | 2.3909 |
| Preferred Stock - Non Redeemable, Net | 129.577 | ||||
| Short Term Investments | 1.498 | 90.411 | 104.86 | 59.337 | |
| Long Term Investments | 0 | 1.522 | 23.946 | 7.056 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 34.296 | 49.067 | 63.861 | 54.727 | 69.149 |
| Cash and Short Term Investments | 31.608 | 45.555 | 61.385 | 53.112 | 66.098 |
| Cash & Equivalents | 17.738 | 32.797 | 61.385 | 51.614 | 50.368 |
| Short Term Investments | 13.87 | 12.758 | 0 | 1.498 | 15.73 |
| Prepaid Expenses | 2.688 | 3.512 | 2.476 | 1.615 | 3.051 |
| Total Assets | 47.578 | 63.199 | 80.809 | 73.729 | 83.496 |
| Property/Plant/Equipment, Total - Net | 12.384 | 12.967 | 16.168 | 18.091 | 13.536 |
| Property/Plant/Equipment, Total - Gross | 12.711 | 13.058 | 23.495 | 26.634 | 21.399 |
| Accumulated Depreciation, Total | -0.327 | -0.091 | -7.327 | -8.543 | -7.863 |
| Long Term Investments | 0 | 0 | |||
| Other Long Term Assets, Total | 0.898 | 1.165 | 0.78 | 0.911 | 0.811 |
| Total Current Liabilities | 18.106 | 25.334 | 44.173 | 52.433 | 54.061 |
| Accounts Payable | 3.435 | 3.627 | 4.002 | 4.712 | 2.64 |
| Accrued Expenses | 14.671 | 17.259 | 17.816 | 16.784 | 17.458 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0 | 4.448 | 22.355 | 30.937 | 33.963 |
| Total Liabilities | 43.037 | 60.201 | 80.094 | 68.33 | 66.584 |
| Total Long Term Debt | 8.827 | 6.781 | 5.246 | 0 | 0 |
| Other Liabilities, Total | 16.104 | 28.086 | 30.675 | 15.897 | 12.523 |
| Total Equity | 4.541 | 2.998 | 0.715 | 5.399 | 16.912 |
| Common Stock | 0.001 | 0.004 | 0.004 | 0.004 | 0.004 |
| Additional Paid-In Capital | 369.141 | 365.79 | 364.572 | 357.921 | 351.04 |
| Retained Earnings (Accumulated Deficit) | -364.602 | -362.801 | -363.861 | -352.523 | -334.104 |
| Other Equity, Total | 0.001 | 0.005 | 0 | -0.003 | -0.028 |
| Total Liabilities & Shareholders’ Equity | 47.578 | 63.199 | 80.809 | 73.729 | 83.496 |
| Total Common Shares Outstanding | 4.10877 | 3.79726 | 3.75957 | 3.57867 | 3.32287 |
| Long Term Debt | 8.827 | 6.781 | 5.246 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -67.731 | -116.721 | -49.908 | -55.572 | -27.366 |
| Cash From Operating Activities | -89.182 | -122.154 | -8.616 | -2.891 | -27.126 |
| Cash From Operating Activities | 2.357 | 2.19 | 2.082 | 0.9 | 0.644 |
| Non-Cash Items | 9.77 | 12.287 | 5.783 | 2.732 | 0.672 |
| Changes in Working Capital | -33.578 | -19.91 | 33.427 | 49.049 | -1.076 |
| Cash From Investing Activities | 89.737 | 34.354 | -63.626 | -69.315 | -0.663 |
| Capital Expenditures | -0.347 | -0.1 | -0.683 | -3.516 | -0.663 |
| Other Investing Cash Flow Items, Total | 90.084 | 34.454 | -62.943 | -65.799 | 0 |
| Cash From Financing Activities | 6.372 | 111.523 | 4.676 | 71.449 | 88.326 |
| Issuance (Retirement) of Stock, Net | 6.372 | 111.523 | 4.676 | 71.449 | 89.986 |
| Issuance (Retirement) of Debt, Net | 0 | 0 | |||
| Net Change in Cash | 6.927 | 23.723 | -67.566 | -0.757 | 60.537 |
| Financing Cash Flow Items | -1.66 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -11.338 | -67.731 | -49.312 | -37.672 | -20.321 |
| Cash From Operating Activities | -19.286 | -89.182 | -70.792 | -46.841 | -25.238 |
| Cash From Operating Activities | 0.662 | 2.357 | 1.679 | 1.152 | 0.604 |
| Non-Cash Items | 1.598 | 9.77 | 8.064 | 6.139 | 3.308 |
| Changes in Working Capital | -10.208 | -33.578 | -31.223 | -16.46 | -8.829 |
| Cash From Investing Activities | 2.438 | 89.737 | 75.49 | 69.84 | 30.459 |
| Capital Expenditures | -0.347 | -0.319 | -0.053 | ||
| Other Investing Cash Flow Items, Total | 2.438 | 90.084 | 75.809 | 69.893 | 30.459 |
| Cash From Financing Activities | 26.619 | 6.372 | 0.983 | 0.882 | 0.83 |
| Issuance (Retirement) of Stock, Net | 1.619 | 6.372 | 0.983 | 0.882 | 0.83 |
| Net Change in Cash | 9.771 | 6.927 | 5.681 | 23.881 | 6.051 |
| Financing Cash Flow Items | |||||
| Issuance (Retirement) of Debt, Net | 25 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Hunt (Ronald M) | Individual Investor | 1.9155 | 322399 | 3035 | 2023-10-01 | HIGH |
| BioImpact Capital LLC | Investment Advisor/Hedge Fund | 1.8993 | 319671 | 0 | 2023-06-30 | MED |
| New Leaf Venture Partners LLC | Venture Capital | 1.8755 | 315670 | 0 | 2023-06-30 | LOW |
| MPM Capital Inc. | Investment Advisor/Hedge Fund | 1.8605 | 313139 | 0 | 2023-06-30 | LOW |
| Arix Bioscience Investments Limited | Venture Capital | 1.3017 | 219092 | 0 | 2023-03-23 | |
| Franklin Advisers, Inc. | Investment Advisor/Hedge Fund | 0.7862 | 132329 | 0 | 2023-06-30 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 0.6851 | 115315 | 0 | 2023-06-30 | LOW |
| Invus Public Equities Advisors, LLC | Investment Advisor | 0.5941 | 100000 | 0 | 2023-06-30 | MED |
| OrbiMed Advisors, LLC | Investment Advisor/Hedge Fund | 0.3691 | 62122 | 0 | 2023-06-30 | LOW |
| Cormorant Asset Management, LP | Hedge Fund | 0.3212 | 54060 | 0 | 2023-06-30 | LOW |
| Kennedy Capital Management, Inc. | Investment Advisor | 0.3148 | 52993 | 0 | 2023-06-30 | MED |
| Lion Point Capital, L.P. | Hedge Fund | 0.2712 | 45651 | 28723 | 2023-06-30 | HIGH |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.2026 | 34106 | -4965 | 2023-06-30 | LOW |
| Tekla Capital Management LLC | Investment Advisor | 0.1544 | 25991 | 0 | 2023-06-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.1286 | 21643 | 0 | 2023-06-30 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.1269 | 21360 | 1718 | 2023-06-30 | HIGH |
| Millennium Management LLC | Hedge Fund | 0.0987 | 16620 | -48662 | 2023-06-30 | HIGH |
| Myers (Scott Dunseth) | Individual Investor | 0.0928 | 15618 | 5797 | 2023-10-01 | |
| Erbez (Georgia L) | Individual Investor | 0.0583 | 9821 | 0 | 2023-04-05 | |
| Telemetry Investments, L.L.C. | Hedge Fund | 0.0553 | 9300 | 9300 | 2022-12-31 | HIGH |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Harpoon Therapeutics, Inc. Company profile
About Harpoon Therapeutics Inc
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in the development of a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The Company is engaged in developing pipeline of novel T cell engagers using TriTACs, focused on the treatment of solid tumors and hematologic malignancies. It has also nominated its clinical candidate using ProTriTAC platform, a prodrug version of TriTAC platform, designed to expand the target space for T cell engagers and bring the benefits of TriTACs to the patients. The Company’s four TriTAC product candidates include HPN424, HPN536, HPN217 and HPN328. The Company ProTriTAC product candidate include HPN601.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Harpoon Therapeutics Inc revenues increased 36% to $23.7M. Net loss increased from $49.9M to $116.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing increase of 33% to $67.3M (expense), Stock-based Compensation in R&D increase from $2M to $4.8M (expense).
| Industry: | Bio Therapeutic Drugs |
611 Gateway Boulevard, Suite 400
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
Income Statement
- Annual
- Quarterly
News
December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com